RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.19
• 52-Week Range: N/A
• Volume: 63.96 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RVLP Stock Analysis - Frequently Asked Questions

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals PLC (NASDAQ:RVLP) announced its quarterly earnings results on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The firm had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million.

What other stocks do shareholders of RVL Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN), Coda Octopus Group (CODA) and Fission Uranium (FCUUF).

Company Calendar

• Last Earnings: 3/20/2023
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RVLP
• CIK: 1739426
• Web: www.osmotica.com
• Phone: (908) 809-1300
• Fax: N/A
• Employees: 125
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $49.72 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 111,410,000
• Free Float: 106,504,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A